Globally, over 50% of those infected with HIV are women, and annually, ~50% of all pregnancies are unintended. Therefore, there is a critical need to promote female-controlled methods of multipurpose prevention and delivery strategies that can be disassociated from the sex act. Intravaginal rings are well tolerated by women, are efficacious for contraception and hormone replacement therapy, and have high patient acceptability and compliance1-4. However, developing effective multipurpose IVRs is challenging due to the limitations of current engineering processes5-6, and differences in drug properties and release rates, thus mandating drug-specific customized IVR designs. Our goal is to address these limitations by revolutionizing the engineering process of intravaginal rings using a state-of-the-art 3D printing process known as the continuous liquid interface production (CLIP?)7. Using CLIP, we can engineer IVRs with complex geometries that cannot be achieved with traditional injection molding or extrusion. The complex geometries within the ring will allow us to precisely fine-tune diffusion and release of drugs from the IVR, and achieve near complete release of drugs from the IVR. More importantly, with CLIP, we can manufacture multipurpose IVRs that can integrate 2 or more drugs to prevent against unintended pregnancies and STIs (HIV, HSV-2, HPV) in a rapid and cost effective single-step process. In this NGM R01 grant and building on our existing data, we propose a comprehensive evaluation of this innovative approach using highly relevant animal models as invaluable preclinical tools to assess the safety and pharmacokinetic profiles of 3D CLIP MPT. This cutting edge combined approach will be utilized to evaluate the scientific premise of our proposal in sheep and macaques to investigate the safety and efficacy of a unique and highly innovative 3D printed multipurpose IVR technology.

Public Health Relevance

The benefit of multipurpose prophylaxis to women with high risk of HIV/STIs infection is significant. Long-acting intravaginal formulations providing steady release over weeks or months of antiretroviral drugs in combination with a contraceptive drug can potentially increase compliance to STIs and unintended pregnancy prophylactic regimen and transform the HIV prevention landscape. The overarching goal of this proposal is to develop and evaluate an innovative approach to multipurpose intravaginal rings that can contribute to curb the HIV epidemic.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Turpin, Jim A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Biomedical Engineering
Schools of Medicine
Chapel Hill
United States
Zip Code